The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Expression of soluble DC-HIL/gpnmb receptor in the blood of metastatic non-small cell lung carcinoma treated with anti-PD1/PDL1 monoclonal antibodies.
 
Jin-Sung Chung
No Relationships to Disclose
 
Vijay Ramani
No Relationships to Disclose
 
Masato Kobayashi
No Relationships to Disclose
 
Vinita Popat
No Relationships to Disclose
 
Ponciano D Cruz
Patents, Royalties, Other Intellectual Property - ANTI-DC-HIL ANTIBODIES FOR CANCER DIAGNOSIS, PROGNOSIS AND THERAPY
 
David E. Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Bristol-Myers Squibb; Samsung Bioepis
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - ArQule (Inst); BerGenBio (Inst); ImClone Systems (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.
Travel, Accommodations, Expenses - ArQule; Bristol-Myers Squibb; Lilly; Lilly
 
Kiyoshi Ariizumi
Patents, Royalties, Other Intellectual Property - ANTI-DC-HIL ANTIBODIES FOR CANCER DIAGNOSIS, PROGNOSIS AND THERAPY